BioMarin Pharmaceutical Inc. (BIT:1BMRN)
45.28
0.00 (0.00%)
At close: Oct 31, 2025
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $776.13M USD in the quarter ending September 30, 2025, with 4.08% growth. This brings the company's revenue in the last twelve months to $3.09B, up 12.39% year-over-year. In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth.
Revenue (ttm)
$3.09B
Revenue Growth
+12.39%
P/S Ratio
3.38
Revenue / Employee
$1.02M
Employees
3,040
Market Cap
8.92B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Stellantis | 146.12B |
| Eni S.p.A. | 86.56B |
| Enel SpA | 77.79B |
| Assicurazioni Generali | 56.79B |
| Intesa Sanpaolo | 25.71B |
| UniCredit | 24.85B |
| Prysmian | 19.85B |
| Leonardo S.p.a. | 18.70B |